Clinical Trials in Progress — NEW Program!
Don't miss this unique opportunity to introduce your clinical trials to the global urologic community!
About the Program
Clinical Trials in Progress is an innovative new program designed to increase awareness of important clinical trials that are expected to influence practice when they are ultimately reported and/or published.
Investigators can present ongoing industry-sponsored or investigator-initiated independent studies that are about to open, currently accruing participants, or in follow-up but have not reported primary findings.
Abstracts should describe the trial's purpose, design and eligibility criteria. Abstracts must not include any results or preliminary data. Abstracts will be reviewed based on their scientific significance, trial design, potential for collaboration and relevance to the AUA Annual Meeting community. See abstract submission guidelines below.
Call for Abstracts
- Now Accepting Abstracts. Submit Now.
- Abstract submission site closes February 1, 2024
Notifications will be sent on or before February 15, 2024
Clinical Trials in Progress will be featured in the new Learning Lab, which showcases engaging presentations at AUA2024. This venue will be adjacent to the Science & Technology Hall and is sure to attract a robust attendance.
Abstract Submission Guidelines
Abstracts should be organized into two sections:
- Scientific rationale for the trial
- Brief description of interventions
- Correlative studies of particular interest
- Trial design and statistical methods, highlighting any new features
- Treatment or interventions planned
- Major eligibility criteria, highlighting any unusual aspects
- Current enrollment status, without providing results or endpoints
- For Phase II and III studies, state how many patients have been enrolled out of the planned total
- For Phase III trials, may state when the data monitoring committee last reviewed the trial and what it recommended
- The trial must be registered, open, and enrolling patients.
- The abstract must not contain preliminary data or results.
Abstract Review Criteria
- Strength of Science — Does the trial address an important and new question?
- Trial Design — Are the eligibility criteria, study endpoints, and planned analysis well-defined?
- Collaboration — Is there potential for investigator collaboration?
- Relevance — Will the results be relevant and of interest to the AUA Annual Meeting community?
- Proprietary drug names or the names of drug manufacturers are not allowed in the title or body of the abstract. If necessary, the proprietary drug name may be included in parentheses directly after the generic name on first use.
- Information about pricing, fees, or reimbursement related to trial participation is not allowed.
- Accepted Clinical Trials in Progress will be scheduled in the Learning Lab according to topic category.
- Presentations will be approximately 10 to 20minutes in length, approximately 10 minutes to present with an additional 10 minutes of questions/discussion.
- The presenting author should be the Principal Investigator.